Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Company Presentation - AnaptysBio Inc's president and CEO Daniel Faga will present at the 43rd Annual J P Morgan Healthcare Conference on January 14 2025 at 4 30pm PT 7 30pm ET [1] - A live webcast of the presentation will be available on the investor section of the Anaptys website with a replay available for at least 30 days following the event [2] Company Overview - AnaptysBio is a clinical-stage biotechnology company focused on innovative immunology therapeutics for autoimmune and inflammatory diseases [3] - The company's lead program rosnilimab is in Phase 2b trials for rheumatoid arthritis and Phase 2 trials for ulcerative colitis [3] - AnaptysBio's portfolio includes ANB033 in Phase 1 trials and ANB101 soon to enter clinical development [3] - The company has licensed multiple therapeutic antibodies to GSK including an anti-PD-1 antagonist and an anti-TIM-3 antagonist [3] Contact Information - Nick Montemarano Senior Director of Investor Relations and Strategic Communications can be reached at 858 732 0178 or investors@anaptysbio com [4]